Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1996-01-23
1998-04-21
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241601, 4241991, 4353201, 514 44, 536 232, A61K 4500, A61K 3942, A61K 3800, C12N 1500
Patent
active
057414920
ABSTRACT:
Polyenv vaccines are provided that comprise mixtures of at least 4-40 to about 10,000 different recombinant vaccinia viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and vaccinia viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection.
REFERENCES:
patent: 5081226 (1992-01-01), Berzofsky et al.
patent: 5169763 (1992-12-01), Kieny et al.
Belshe, R. B. et al., "HIV Infection in Vaccinated Volunteers," J. Amer. Medical Assoc. 272(6):431 (1994).
Burns, D. P. W. and R. C. Desrosiers, "Envelope Sequence Variation, Neutralizing Antibodies, and Primate Lentivirus Persistence," Curr. Top. Microbiol. Immunol. 188:185-219 (1994).
Chakrabarti, S. et al., "Vaccinia Virus Expression Vector: Coexpression of .beta.-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," Mol. Cell. Biol. 5(12):3403-3409 (1985).
Cohen, J., "The HIV Vaccine Paradox," Science 264:1072-1074 (1994).
Cooney, E. L. et al., "Enhanced immunity of human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein," Proc. Natl. Acad. Sci. USA 90:1882-1886 (1993).
D'Hondt, E., "Possible approaches to develop vaccines against hepatitis A," Vaccine 10(Suppl. 1):S48-S52 (1992).
Enami, M. and P. Palese, "High-Efficiency Formation of Influenza Virus Transfectants," J. Virol. 65(5):2711-2713 (1991).
Enami, M. et al., "Introduction of site-specific mutations into the genome of influenza virus," Proc. Natl. Acad. Sci. USA 87:3802-3805 (1990).
Gorse, G. J., "Phase I/II Trials of Preventive HIV Vaccine Candidates. Dose and Schedule: Summary," AIDS Res. Human Retroviruses 10(Suppl. 2):S141-S143 (1994).
Graham, B. S. et al., "Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with rgp160 in Vaccinia-Naive Adults," J. Inf. Dis. 167:533-537 (1993).
Graham, B. S. et al., "Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial," J. Inf. Dis. 166:244-252 (1992).
Grunwald-Beard, L. et al., "Killing of Burkitt-lymphoma-derived Daudi cells by ultraviolet-inactivated vaccinia virus," J. Cancer Res. Clin. Oncol. 117:561-567 (1991).
Hallenberger, S. et al., "Secretion of a Truncated Form of the Human Immunodeficiency Virus Type I Envelope Glycoprotein," Virol. 193:510-514 (1993).
Ito, T. et al., "Evolutionary Analysis of the Influenza A Virus M Gene with Comparison of the M1 and M2 Proteins," J. Virol. 65(10):5491-5498 (1991).
Javaherian, K. et al., "Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein," Proc. Natl. Acad. Sci. USA 86:6768-6772 (1989).
Keefer, M. C. et al., "Safety Profile of HIV Vaccination: First 1000 Volunteers of AIDS Vaccine Evaluation Group," AIDS Res. Human Retroviruses 10(Suppl. 2):S139-S140 (1994).
Kilpatrick, D. R. et al., "Effects of Deletion of the Cytoplasmic Domain upon Surface Expression and Membrane Stability of a Viral Envelope Glycoprotein," J. Biol. Chem. 262(33):16116-16121 (1987).
McElrath, M. J. et al., "Immune Responses Elicited by Recombinant Vaccinia-Human Immunodeficiency Virus (HIV) Envelope and HIV Envelope Protein: Analysis of the Durability of Responses and Effect of Repeated Boosting," J. Inf. Dis. 169:41-47 (1994).
Richman, D. D., "Resistance, Drug Failure, and Disease Progression," AIDS Res. Human Retroviruses 10(8):901-905 (1994).
Richman, D. D., "Resistance of Clinical Isolates of Human Immunodeficiency Virus to Antiretroviral Agents," Antimicrob. Agents Chemother. 37(6):1207-1213 (1993).
Richman, D. D., "HIV Drug Resistance," AIDS Res. Human Retroviruses 8(6):1065-1071 (1992).
Starcich, B. R. et al., "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS," Cell 45:637-648 (1986).
Zagury, D. et al., "A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS," Nature 332:728-731 (1988).
Girard, M. et al., "Immunogenicity of Potential HIV Vaccines in Chimpanzees," Int. Conf. AIDS 5:541 Abstract Th.C.O.47 (1989).
Eichberg, J. W., "Experience with Seventeen HIV Vaccine Efficacy Trials in Chimpanzees," Int. Conf. AIDS 7(2):88 Abstract F.A.2 (1991).
Gritz et al. (1990) J. Virol. 64:5948-57.
Perales et al. (1995) J. AIDS & Human Retrovirol. 10:27-35.
Rencher et al. (1995) AIDS Res. Human Retroviruses 11:1131-3.
Ruby et al. (1990) Immun. Cell Biol. 68:113-7.
Fahey et al., Status of immune-based therapies in HIV infection and AIDS Clin. Exp. Immunol. (Jan. 1992) 88, 1-5.
Fox, J.L., No winners against AIDS, Bio/Technology, (1994) vol. 12, Feb. p. 128.
Hird et al., Immunotherapy with Monoclonal Antibodies, Genes and Cancer, Edited by Carney et al., 183-189, see p. 185, paragraph 1, 1990.
Berman et al., Protection of chimpanzees from infection by HV-1 after vaccination with recombinant glycoprotein gp120 but not gp160, Nature, vol. 345, pp. 622-625, see Abstract, col. 3, line 62, col. 8, "Example 2", Jun. 1990.
Stephens et al., Antibodies are produced to the variable regions of the external envelope glycoprotein of HIV-1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine, J Gen Virol, 73, 1099-1106, see Abstract, p, 1992.
Dallo et al, Human Immune Response elicited by Highly Attenuated Variants of Vaccinia Virus and by an Attenuated Recombinant Expressing HIV-1 Envelope Protein, Virol 173, 323-329, see Abstract, Jul. 1989.
Hurwitz Julia L.
Owens Randall J.
Achutamurthy Ponnathapura
Park Hankyel T.
St. Jude Children's Research Hospital
LandOfFree
Preparation and use of viral vectors for mixed envelope protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation and use of viral vectors for mixed envelope protein , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and use of viral vectors for mixed envelope protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2055311